Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

A systematic review of botulinum toxin in the management of patients with temporomandibular disorders and bruxism

Abstract

Introduction The medical and cosmetic use of botulinum toxin (BTX) is now widespread. With an increased number of clinicians adopting the use of BTX in the management of temporomandibular disorders (TMD) and/or bruxism, as either a standalone treatment or as an adjunct, affirmation is required in regards to whether it has a clinically justifiable position among the current spectrum of available treatment modalities.

Objectives To establish the usefulness of BTX when treating patients with TMD and/or bruxism, and thereby determine whether there may be an appropriate purpose for the prescription of BTX in the management of these patients.

Data sources and data selection A systematic review of the relevant literature was conducted. The literature search was carried out by applying key terms to appropriate data sources (Medline, Embase, Pubmed, Cochrane Central Register of Controlled Trials, and OpenSIGLE). The resultant papers were subjected to inclusion and exclusion criteria, which were then assessed for bias using a framework outlined in the Cochrane Handbook.

Results A total of 11 trials met the inclusion criteria. The primary outcome measure was changes in pain experience in groups that had been treated with BTX, relative to an appropriate control group. Secondary outcomes included changes in the frequency of bruxism events, changes in maximum mouth opening, changes in occlusal force and changes in electromyography (EMG) readings of muscles of mastication.

Conclusion The evidence to support the use of BTX in the management of TMD and/or bruxism is not entirely unequivocal. A number of studies that have met the inclusion criteria have shown promising results and thereby justify further investigation. Given the current evidence, BTX should certainly be considered but due to financial implications and possible side effects, it seems appropriate that conservative options, such as self-management with explanation and physical therapies, should be exhausted first.

Your institute does not have access to this article

Relevant articles

Open Access articles citing this article.

Access options

Buy article

Get time limited or full article access on ReadCube.

$32.00

All prices are NET prices.

References

  1. American Association for Dental Research. Temporomandibular Disorders (TMD). 2015. Available at http://www.iadr.org/AADR/About-Us/Policy-Statements/Science-Policy/Temporomandibular-Disorders-TMD (accessed April 2019).

  2. Durham J, Aggarwal V, Davies S J et al. Temporomandibular Disorders (TMDs): an update and management guidance for primary care from the UK Specialist Interest Group in Orofacial Pain and TMDs (USOT). 2013. Available at https://www.rcseng.ac.uk/-/media/files/rcs/fds/publications/temporomandibular-disorders-2013.pdf (accessed April 2019).

  3. Dworkin S F, Huggins K H, LeResche L et al. Epidemiology of signs and symptoms in temporomandibular disorders: clinical signs in cases and controls. J Am Dent Assoc 1990; 120: 273-281.

  4. Goulet J P, Lavigne G J, Lund J P. Jaw pain prevalence among Frenchspeaking Canadians in Québec and related symptoms of temporomandibular disorders. J Dent Res 1995; 74: 1738-1744.

  5. Kelleher M, Ray-Chaudhuri A, Khawaja N. Patients' Priorities and Attitudes Towards Their Temporo-Mandibular Disorders. Prim Dent J 2015; 4: 17-21.

  6. Huang G J, LeResche L, Critchlow C W, Martin M D, Drangsholt M T. Risk factors for diagnostic subgroups of painful temporomandibular disorders (TMD). J Dent Res 2002; 81: 284-288.

  7. Macfarlane T V, Grey R J, Kincey J, Worthington H V. Factors associated with the temporomandibular disorder, pain dysfunction syndrome (PDS): Manchester case-control study. Oral Dis 2001; 7: 321-330.

  8. Velly A M, Gornitsky M, Philippe P. Contributing factors to chronic myofascial pain: a case-control study. Pain 2003; 104: 491-499.

  9. Lobbezoo F, Ahlberg J, Glaros A G et al. Bruxism defined and graded: an international consensus. J Oral Rehabil 2013; 40: 2-4.

  10. Lobbezoo F, Ahlberg D, Manfredini D, Winocur E. Review article: are bruxism and the bite causally related? J Oral Rehabil 2012; 39: 489-501.

  11. Guarda-Nardini L, Manfredini D, Salamone M, Salmaso L, Tonello S, Ferronato G. Efficacy of botulinum toxin in treating myofascial pain in bruxers: a controlled placebo pilot study. Cranio 2008; 26: 126-135.

  12. Lyons M F. Current practice in the management of temporomandibular disorders. Dent Update 2008; 35: 314-316: 318.

  13. Schiffman E, Ohrbach R, Truelove E et al. Diagnostic Criteria for Temporomandibular Disorders (DC/TMD) for Clinical and Research Applications: Recommendations of the International RDC/TMD Consortium Network and Orofacial Pain Special Interest Group†. J Oral Facial Pain Headache 2014; 28: 6-27.

  14. Dimitroulis G. The role of surgery in the management of the TMJ: a critical review of the literature. Part 1. Int J Oral Maxillofac Surg 2005; 34: 107-113.

  15. Dimitroulis G. The role of surgery in the management of the TMJ: a critical review of the literature. Part 2. Int J Oral Maxillofac Surg 2005; 34: 231-237.

  16. Al-Ani M Z, Davies S J, Grey R J, Sloan P, Glenny A M. Stabilisation splint therapy for temporomandibular pain dysfunction syndrome. Cochrane Database Syst Rev 2004; CD002778.

  17. Kacer K A, Valiathan M, Narendran S, Hans M G. Retainer wear and compliance in the first 2 years after active orthodontic treatment. Am J Orthod Dentofacial Orthop 2010; 138: 592-598.

  18. Lindfors E, Helkimo M, Magnusson T. Patients' adherence to hard acrylic interocclusal appliance treatment in general dental practice in Sweden. Swed Dent J 2011; 35: 133-142.

  19. Roter D L, Hall J A, Merisca R, Nordstrom B, Cretin D, Svarstad B. Effectiveness of interventions to improve patient compliance: a meta-analysis. Med Care 1998; 36: 1138-1161.

  20. Wig A D, Aaron L A Turner J A, Huggins K H, Truelove E. Short-term clinical outcomes and patient compliance with temporomandibular disorder treatment recommendations. J Orofac Pain 2004; 18: 203-213.

  21. Naumann M, So Y, Argoff C E et al. Assessment: botulinum neurotoxin in the treatment of autonomic disorders and pain (an evidence-based review): report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology. Neurology 2008; 70: 1707-1714.

  22. Gadhia K, Walmsley A D. Facial aesthetics: is botulinum toxin treatment effective and safe? A systematic review of randomised controlled trials. Br Dent J 2009; 207: E9.

  23. Sellin L C, Thesleff S. Preand post-synaptic actions of botulinum toxin at the rat neuromuscular junction. J Physiol 1981; 317: 487-495.

  24. Aoki K R. Review of a proposed mechanism for the antinociceptive action of botulinum toxin type A. Neurotoxicology 2005; 26: 785-793.

  25. Purkiss J, Welch M, Doward S, Foster K. Capsaicin-stimulated release of substance P from cultured dorsal root ganglion neurons: involvement of two distinct mechanisms. Biochem Pharmacol 2000; 59: 1403-1406.

  26. Scottish Intercollegiate Guidelines Network. Algorithm for classifying study design for questions of effectiveness. Available at https://www.sign.ac.uk/assets/study_design.pdf (accessed April 2019).

  27. Guarda-Nardini L, Stecco A, Stecco C, Masiero S, Manfredini D. Myofascial pain of the jaw muscles: comparison of short-term effectiveness of botulinum toxin injections and fascial manipulation technique. Cranio 2012; 30: 95-102.

  28. Ernberg M, Hedenberg-Magnusson B, List T, Svensson P. Efficacy of botulinum toxin typeA for treatment of persistent myofascial TMD pain: A randomized, controlled, double-blind multicentre study. Pain 2011; 152: 1988-1996.

  29. von Lindern J J, Niederhagen B, Berge S, Appel T. Type A botulinum toxin in the treatment of chronic facial pain associated with masticatory hyperactivity. J Oral Maxillofac Surg 2003; 61: 774-778.

  30. Kurtoglu C, Gur O H, Kurkcu M, Sertdemir Y, Guler-Uysal F, Uysal H. Effect of botulinum toxinA in myofascial pain patients with or without functional disc displacement. J Oral Maxillofac Surg 2008; 66: 1644-1651.

  31. Nixdorf D R, Heo G, Major P W. Randomized controlled trial of botulinum toxin A for chronic myogenous orofacial pain. Pain 2002; 99: 465-473.

  32. Guarda-Nardini L, Manfredini D, Salamone M, Salmaso L, Tonello S, Ferronato G. Efficacy of botulinum toxin in treating myofascial pain in bruxers: a controlled placebo pilot study. Cranio 2008; 26: 126-135.

  33. Lee S J, McCall W D Jr, Kim Y K, Chung S C, Chung J W. Effect of botulinum toxin injection on nocturnal bruxism: a randomized controlled trial. Am J Phys Med Rehabil 2010; 89: 16-23.

  34. De Carli B M, Magro A K, Souza-Silva B N et al. The effect of laser and botulinum toxin in the treatment of myofascial pain and mouth opening: A randomized clinical trial. J Photochem Photobiol B 2016; 159: 120-123.

  35. Zhang L D, Liu Q, Zou D R, Yu L F. Occlusal force characteristics of masseteric muscles after intramuscular injection of botulinum toxin A (BTX A) for treatment of temporomandibular disorder. Br J Oral Maxillofac Surg 2016; 54: 736-740.

  36. Chaurand J, Pacheco-Ruíz L, Orozco-Saldívar H, López-Valdés J Efficacy of botulinum toxin therapy in treatment of myofascial pain. J Oral Sci 2017; 59: 351-356.

  37. Patel A A, Lerner M Z, Blitzer A. IncobotulinumtoxinA Injection for Temporomandibular Joint Disorder: A Randomized Controlled Pilot Study. Ann Otol Rhinol Laryngol 2017; 126: 328-333.

  38. von Lindern J J. Type A Botulinum toxin in the treatment of chronic facial pain associated with temporo-mandibular dysfunction. Acta Neurol Belg 2001; 101: 39-41.

  39. Sidebottom A J, Patel A A, Amin J. Botulinum injection for the management of myofascial pain in the masticatory muscles. A prospective outcome study. Br J Oral Maxillofac Surg 2013; 51: 199-205.

  40. Lee K M, Chow J, Hui E, Li W. Botulinum Toxin Type A Injection for the Management of Myofascial Temporomandibular Pain Disorder. Asian J Oral Maxillofac Surg 2005; 17: 100-103.

  41. Molina O F, dos Santos J Jr, Nelson S J, Grossman E. Prevalence of modalities of headaches and bruxism among patients with craniomandibular disorder. Cranio 1997; 15: 314-325.

  42. Shim Y J, Lee M K, Kato T, Park H U, Heo K, Kim S T. Effects of botulinum toxin on jaw motor events during sleep in sleep bruxism patients: a polysomnographic evaluation. J Clin Sleep Med 2014; 10: 291-298.

  43. Sener H O, Oral N, Keyf F. Intramasseteric botulinum toxin injection is as effective as oral overnight splint in nocturnal bruxism. Cephalalgia 2007; 27: 1191.

  44. Bolayir G, Bolayir E, Coskun A, Özdemir A K, Topaktaş S. Botulinum toxin typeA practice in bruxism cases. Neurol Psychiat Br 2005; 12: 43-45.

  45. Ivanhoe C B, Lai J M, Francisco G E. Bruxism after brain injury: Successful treatment with botulinum toxinA. Arch Phys Med Rehabil 1997; 78: 1272-1273.

  46. Watts M W, Tan E K, Jankovic J: Bruxism and cranialcervical dystonia: Is there a relationship? Cranio 1999; 17: 196-201.

  47. Tan E K, Jankovic J. Treating severe bruxism with botulinum toxin. J Am Dent Assoc 2000; 131: 211-216.

  48. Pidcock F S, Wise J M, Christensen J R. Treatment of severe post-traumatic bruxism with botulinum toxinA: case report. J Oral Maxillofac Surg 2002; 60: 115-117.

  49. See S J, Tan E K. Severe amphetamine-induced bruxism: Treatment with botulinum toxin. Acta Neurol Scand 2003; 107: 161-163.

  50. Nash M C, Ferrell R B, Lombardo M A, Williams R B. Treatment of bruxism in Huntington's disease with botulinum toxin. J Neuropsychiatry Clin Neurosci 2004; 16: 381-382.

  51. Monroy P G, da Fonseca M A. The use of botulinum toxinA in the treatment of severe bruxism in a patient with autism: a case report. Spec Care Dentist 2006; 26: 37-39.

  52. Jensen M P. Validity of self-report and observational measures. In Jensen T S, Turner J A, Wiesenfeld-Hallin Z (eds) Proceedings of the 8th World Congress on Pain. pp 637-661.Seattle, WA: IASP Press, 1997.

  53. Conti P C, de Azevedo L R, de Souza N V, Ferreira F V. Pain measurement in TMD patients: evaluation of precision and sensitivity of different scales. J Oral Rehabil 2001; 28: 534-539.

  54. Higgins J P T, Green S (eds). Cochrane Handbook for Systematic Reviews of Interventions. Version 5.1.0. London: The Cochrane Collaboration, 2011.

  55. Gerwin R. Botulinum toxin treatment of myofascial pain: a critical review of the literature. Curr Pain Headache Rep 2012; 16: 413-422.

  56. Klein F H, Brenner F M, Sato M S, Robert F M, Helmer K A Lower facial remodeling with botulinum toxin type A for the treatment of masseter hypertrophy. An Bras Dermatol 2014; 89: 878-884.

  57. Rollman G B, Gillespie J M. The role of psychosocial factors in temporomandibular disorders. Curr Rev Pain 2000; 4: 71-81.

Download references

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Jalpesh Patel.

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Patel, J., Cardoso, J. & Mehta, S. A systematic review of botulinum toxin in the management of patients with temporomandibular disorders and bruxism. Br Dent J 226, 667–672 (2019). https://doi.org/10.1038/s41415-019-0257-z

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/s41415-019-0257-z

Further reading

Search

Quick links